53175 Bonn, de
+49 (89) 54043045
New capital for the navigated tumor surgery: FVW and Clusterfonds Innovation invest in SurgicEye
In the past 12 months SurgicEye, a spinoff from "Technische Universität München", turned its innovative concept for intraoperative functional imaging into a CE labeled product. This was achieved with the support of the seed investment of "High-Tech Gründerfonds" and "Seedfonds Technologie Bayerns" of Bayern Kapital. Along with this new financing round, SurgicEye installed an advisory board with the entrepreneurs, Dr. Friebe, Robert Grüter, Christian Hieronimi, Prof. Dr. Nassir Navab and Dr. Jörg Peter Ströbel, experts in the field of Medical Devices, and in particular, in imaging and navigation technologies.
With the aid of 3D imaging and navigation proposed by SurgicEye, surgical procedures in oncology can be performed in a secure and target oriented. The system is currently in use in the reference centers at Klinikum rechts der Isar in Munich and in Bologna, Italy. Another five reference centers are installed at the moment for the guided treatment breast cancer and melanoma. "The usage of this technology is a quality improvement for the extraction of malign tissue", Dr. Marc Martignoni of "Klinikum rechts der Isar".
The first applications are in breast cancer surgery, as well as melanoma. The SurgicEye system enables operations that are at the same time minimally invasive and complete. This results thus in a gentle, but optimal intervention for the patient. The SurgicEye solution outperforms all currently performed radioguided procedures.
"In addition to the investment for the market introduction, internationalization and extension, we managed to gain experience in the market and enterprise growth trough our new strong partners and advisory board members" explains Dr. Joerg Traub, CEO of the SurgicEye GmbH.
"I am convinced that SurgicEye's innovative approaches for the optimization of tumor surgery will set an important milestone towards quality assurance in patienttailored surgical treatment of cancer" states Dr. Michael Friebe, FVW Investment Manager and Partner, as well as newly nominated Chairman of SurgicEye. "The team of SurgicEye merges entrepreneurial, medical and technical competences. It is thus well prepared for the upcoming challenges of growth" comments Monika Steger, Team Leader of Bayern Kapital. Dr. Bernd Goergen, Senior Investment Manager of High-Tech Gründerfonds, appends: "We are enthusiastic about the development of SurgicEye and see in the new involvement of industrial experts in medical imaging and navigation a confirmation of our early investment".
About SurgicEye GmbH:
SurgicEye offers solutions for intraoperative imaging and instrument navigation. The first product, the Confident Surgery Suite 300, of SurgicEye implements the so called freehand SPECT technology for detection, localization and guided biopsy of sentinel lymph nodes in breast cancer. Clinical investigations in other tumor surgery domains promise a wide application domain and huge potential for quality assurance during surgery. It enables surgical procedures to be more sensitive, more reliable and less invasive.
About FVW investments for your health Beteiligungs GmbH & Co.KG:
FVW is specialized on seed and growth finanancing in life science with a focus on medical devices. Partners of FVW invest their own capital in ventures where they see their involvement as a clear asset in terms of market knowledge, networking and technology cooperation. All partners of FVW are experienced and active entrepreneurs.
About Bayern Kapital GmbH:
Bayern Kapital was founded in 1995 as initiative of the Bavarian government to strengthen the future of the region "Offensive Zukunft Bayern", especially to establish and support and invest in new and innovative companies. Up to date Bayern Kapital has invested about 149m Euro in more than 180 innovative High Tech companies. Currently Bayern Kapital manages through eight funds around 190m Euro.
Clusterfonds Innovation, managed by Bayern Kapital, invests in technology startups in cooperation with a lead investor. The lead investor has to actively support the company in strategic planning and market entry. Investments up to 2m Euro are possible.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.